11/21/2013

Tandem Diabetes Care has secured $138 million in its just-completed initial public offering, topping its IPO target of $120 million. The San Diego company is the maker of the touch-screen t:slim system, a pocket-sized insulin delivery device cleared by the FDA in 2011.

Related Summaries